YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer. Wang L, Wang Q, Xu P, Fu L, et al. Br J Cancer 2020;123:1000-1011.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang L, Wang Q, Xu P, Fu L, et al. YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer. Br J Cancer 2020;123:1000-1011.
PMID: 32572172